Brand-heavy companies such as Mankind Pharma, Sun Pharma, Torrent Pharmaceuticals and Eris Lifesciences are expected to ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Shares in Sun Pharma fell sharply after the NSE ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

With no prior business experience, he started his journey with just two employees and transformed his company into a global ...

Sun Pharma faces a delay in the U.S. launch of its drug Leqselvi due to a preliminary injunction by the New Jersey court, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Net profit of drugmaker Sun Pharmaceutical Industries rose 28% year-on-year to ₹3,040 crore for the quarter ended Sepember ...

The US District Court of New Jersey has granted a preliminary injunction delaying the launch of Leqselvi by Sun Pharma. As a result of this court decision, the company is prohibited from launching ...

The company's EBITDA stood at Rs. 3939.0 crore (including other operating revenues), up 23.9 percent, with resulting EBITDA margin of 29.6 percent.

Sun Pharmaceutical Industries Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has ...